Erratum: Expression of Concern: Glucose Deprivation Induces G2/M Transition-Arrest and Cell Death in N-GlcNAc2-Modified Protein-Producing Renal Carcinoma Cells (PLoS ONE (2014) 9:5 (e96168) DOI: 10.1371/journal.pone.0096168);Glucose deprivation induces G2/M transition-arrest and cell death in N-GlcNAc2-modified protein-producing renal carcinoma cells

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Isono, Takahiro ^a   Chano, Tokuhiro ^a   Kitamura, Asuka ^a   Yuasa, Takeshi ^b  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; BUFORMIN; GLUCOSE; GLYCOPROTEIN; N (BETA N ACETYLGLUCOSAMINE); PROTEIN P53; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE; ANTIDIABETIC AGENT; ATF3 PROTEIN, HUMAN; N ACETYLGLUCOSAMINE; TP53 PROTEIN, HUMAN;

ARTICLE; BIOACCUMULATION; BIOSYNTHESIS; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REPRESSION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; KIDNEY CARCINOMA; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN MODIFICATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNFOLDED PROTEIN RESPONSE; UPREGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GLYCOSYLATION; KIDNEY TUMOR; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ACETYLGLUCOSAMINE; ACTIVATING TRANSCRIPTION FACTOR 3; BUFORMIN; CELL DEATH; CELL LINE, TUMOR; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION; GLUCOSE; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY NEOPLASMS; M PHASE CELL CYCLE CHECKPOINTS; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84900406129     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0279155     Document Type: Erratum

References (17)

1. Koppenol WH, Bounds PL, Dang CV (2011) Otto warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 69:325-337.
2. El Mjiyad N, Caro-Maldonado A, Ramirez-Peinado S, Munoz-Pinedo. (2011) Sugar-free approarches to cancer cell killing. Oncogene 30:253-264.
3. Wu H, Ding Z, Hu D, Sun F, Dai C, et al. (2012) Central role of lactic acidosis in cancer cell resistance to glucose deprivation-induced cell death. J Pathol 227:189-99.
4. 2-modified proteins induced under glucose deprivation. PLos One 6: e18959.
5. Isono T, Chano T, Okabe H, Suzaki M. Isono T (2013) Study of global transcriptional changes of N-GlcNAc2 proteins-producing T24 bladder carcinoma cells under glucose deprivation. PLoS One 8:e60397.
6. Hartmann JT, Bokemeyer C (1999) Chemotherapy for renal cell carcinoma. Anticancer Res 19: 1541-3. (Pubitemid 29255643)
7. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-9. (Pubitemid 17064313)
8. Laoukili J, Stahl M, Medema RH (2007) FoxM1: at the crossroads of aging and cancer. Biochem Biophys acta 1775: 92-102.
9. Taylor WR, Stark GR (2001) Regulation of G2/M transition by p53. Oncogene 20:1803-15.
10. Saito S, Furuno A, Sakurai J, Sakamoto A, Park HR, et al. (2009) Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Canser Res 69:4225-34.
11. Matsuo J, Tukumo Y, Saito S, Tsukahara S, Sakurai J, et al. (2012) Hyperactivation of 4E-binding protein 1 as a mediator of biguanaide induced cytotoxicity during glucose deprivation. Mol cancer Ther 11:1082-91.
12. Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, et al. (2012) Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 30:2919-28.
13. Srinivasan R, Linehan WN (2007) Antiangiogenic therapy in renal cell carcinoma: from concept to reality. Nat Clin Pract Urol 4:74-5.
14. Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Ng Boni JP, et al. (2006) A phase I and phaemacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12:5755-63. (Pubitemid 44629606)
15. Gupta A, Ming XF, Carvas JM, Yang Z (2009) The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects. Am J Physiol Heart Circ Physiol 296:H815-H822.
16. Lee AS (2007) GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 67:3496-9.
17. So AY, da la Fuente E, Walter P, Shuman M, Bemales S (2009) The unfolded protein response during prostate cancer development. Cancer Metastasis Rev 28:219-23.